Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support - PubMed (original) (raw)
Clinical Trial
. 1993 Oct 21;329(17):1219-24.
doi: 10.1056/NEJM199310213291702.
Affiliations
- PMID: 7692295
- DOI: 10.1056/NEJM199310213291702
Free article
Clinical Trial
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
O W Press et al. N Engl J Med. 1993.
Free article
Abstract
Background: Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 and 1F5) and anti-CD37 (MB-1) antibodies labeled with iodine-131 in 43 patients with B-cell lymphoma in relapse.
Methods: Sequential biodistribution studies were performed with escalating doses of antibody (0.5, 2.5, and 10 mg per kilogram of body weight) trace-labeled with 5 to 10 mCi of 131I. The doses of radiation absorbed by tumors and normal organs were estimated by serial gamma-camera imaging and tumor biopsies. Patients whose tumors were estimated to receive greater doses of radiation than the liver, lungs, or kidneys (i.e., patients with a favorable biodistribution) were eligible for therapeutic infusion of 131I-labeled antibodies according to a phase 1 dose-escalation protocol.
Results: Twenty-four patients had a favorable biodistribution, and 19 received therapeutic infusions of 234 to 777 mCi of 131I-labeled antibodies (58 to 1168 mg) followed by autologous marrow reinfusion, resulting in complete remission in 16, a partial response in 2, and a minor response (25 to 50 percent regression of tumor) in 1. Nine patients have remained in continuous complete remission for 3 to 53 months. Toxic effects included myelosuppression, nausea, infections, and two episodes of cardiopulmonary toxicity, and were moderate in patients treated with doses of 131I-labeled antibodies that delivered less than 27.25 Gy to normal organs.
Conclusions: High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
Comment in
- Progress in radioimmunotherapy.
Bast RC Jr. Bast RC Jr. N Engl J Med. 1993 Oct 21;329(17):1266-8. doi: 10.1056/NEJM199310213291712. N Engl J Med. 1993. PMID: 8413396 No abstract available.
Similar articles
- Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. Behr TM, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s. Clin Cancer Res. 1999. PMID: 10541379 - Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjögreen K, Wingårdh K, Strand SE. Lindén O, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3287s-3291s. Clin Cancer Res. 1999. PMID: 10541377 - Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Kaminski MS, et al. N Engl J Med. 1993 Aug 12;329(7):459-65. doi: 10.1056/NEJM199308123290703. N Engl J Med. 1993. PMID: 7687326 Clinical Trial. - Radiolabeled antibody therapy of B-cell lymphomas.
Press OW. Press OW. Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65. Semin Oncol. 1999. PMID: 10561019 Review. - Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas.
Press OW, Eary JF, Appelbaum FR, Bernstein ID. Press OW, et al. Cancer Treat Res. 1995;76:281-97. doi: 10.1007/978-1-4615-2013-9_13. Cancer Treat Res. 1995. PMID: 7577340 Review. No abstract available.
Cited by
- Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.
Yang Y, Vedvyas Y, Alcaina Y, Son JY, Min IM, Jin MM. Yang Y, et al. Front Immunol. 2024 Mar 14;15:1355388. doi: 10.3389/fimmu.2024.1355388. eCollection 2024. Front Immunol. 2024. PMID: 38550578 Free PMC article. - From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications.
Gnesin S, Chouin N, Cherel M, Dunn SM, Schaefer N, Faivre-Chauvet A, Prior JO, Delage JA. Gnesin S, et al. EJNMMI Res. 2023 Jun 14;13(1):59. doi: 10.1186/s13550-023-01010-4. EJNMMI Res. 2023. PMID: 37314509 Free PMC article. - Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
Saha A, Blazar BR. Saha A, et al. Front Immunol. 2022 Oct 20;13:1031334. doi: 10.3389/fimmu.2022.1031334. eCollection 2022. Front Immunol. 2022. PMID: 36341432 Free PMC article. Review. - Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.
Sabanathan D, Campbell DH, Velonas VM, Wissmueller S, Mazure H, Trifunovic M, Poursoltan P, Ho Shon K, Mackay TR, Lund ME, Lu Y, Roach PJ, Bailey DL, Walsh BJ, Gillatt D, Gurney H. Sabanathan D, et al. Asia Ocean J Nucl Med Biol. 2021 Spring;9(2):86-100. doi: 10.22038/AOJNMB.2021.55600.1386. Asia Ocean J Nucl Med Biol. 2021. PMID: 34250138 Free PMC article. - 131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors.
Zhang Y, Kupferschlaeger J, Lang P, Reischl G, Handgretinger RJ, Fougère C, Dittmann H. Zhang Y, et al. J Nucl Med. 2022 Feb;63(2):205-211. doi: 10.2967/jnumed.120.261854. Epub 2021 May 28. J Nucl Med. 2022. PMID: 34049985 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous